Stocks and Investing
Stocks and Investing
Thu, June 1, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gena Wang Upgraded (BLUE) to Buy and Increased Target to $8 on, Jun 1st, 2023
Gena Wang of Barclays, Upgraded "bluebird bio, Inc." (BLUE) to Buy and Increased Target from $7 to $8 on, Jun 1st, 2023.
Gena has made no other calls on BLUE in the last 4 months.
There are 5 other peers that have a rating on BLUE. Out of the 5 peers that are also analyzing BLUE, 2 agree with Gena's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Jason Gerberry of "B of A Securities" Maintained at Hold with Decreased Target to $6 on, Thursday, March 30th, 2023
- Luca Issi of "RBC Capital" Reiterated at Hold and Held Target at $8 on, Thursday, March 30th, 2023
These are the ratings of the 3 analyists that currently disagree with Gena
- Eric Joseph of "JP Morgan" Initiated at Buy and Held Target at $7 on, Friday, April 28th, 2023
- Matthew Harrison of "Morgan Stanley" Maintained at Sell with Decreased Target to $3 on, Monday, April 3rd, 2023
- Jack Allen of "Baird" Initiated at Buy and Held Target at $10 on, Tuesday, March 7th, 2023
Contributing Sources